Monthly Archives: November 2022

About the RETAIN study: Improving RETention and viral load outcomes for people taking Antiretroviral therapy through early IdentificatioN of missed doses

Too few South Africans living with HIV achieve viral suppression. Although advances in antiretroviral therapy (ART) have reduced illness and death for people with HIV (PWH), ongoing evidence show gaps in the HIV continuum, including poor tablet taking / adherence and low retention in care, particularly in the first 4 months after ART is started.…

Africa REACH welcomes news that Zimbabwe becomes the first African country to approve injectable PrEP

*This article is based off a press release distributed by DTHF partner, Africa REACH.   The Medicines Control Authority of Zimbabwe recently approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV prevention, making Zimbabwe the first African country to authorize the once-every-two-months injectable PrEP drug. Zimbabwe has a PrEP program…

The SOGI Universe: Which planet do you come from?

People whose sexual orientation and gender identity (SOGI) do not conform to the majority may experience hostility and exclusion in everyday life. Sexual orientation and gender identity are two separate but distinct part of people’s overall identity. Learning about these concepts for the first time can be confusing and overwhelming. Enter the SOGI Universe! The…